Skip to content
Politically.com Search all
Menu

2026 · 3rd Quarter (July 1 - Sep 30)

KALEO

Filed by WINNING STRATEGIES WASHINGTON.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-11-03 06:26:12 UTC.

Source-reported fields

Filing overview

Type
3rd Quarter - Report
Posted
Oct 20, 2026
Income
$10,000.00
Expenses
Not reported
Client
KALEO
Filing UUID
f57d0853-602f-409b-96b9-7c94f2159b49
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

PHA · Pharmacy

Pharmaceutical drug development, including epinephrine for anaphylaxis; drug access and affordability issues

DEF · Defense

Medical countermeasures research and development

BUD · Budget/Appropriations

Medical countermeasures research and development

AVI · Aviation/Airlines/Airports

FAA reauthorization provisions related to emergency medicine.

HCR · Health Issues

Legislation related to prescription drug prices, access to epinephrine in schools, childcare, and other community settings

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.